Advertisement

Pharmacokinetics and disposition of orally administered [2,3-14C] succinimide in the rat

  • K. E. Schulte
  • S. Rendić
  • G. Henke
  • R. I. Mrongovius
Article

Summary

The absorption, distribution, and elimination of radioactivity after the oral administration of14C-labelled succinimide has been investigated at three dosage levels (0.09, 1.0 and 2.0 g/kg). A comparison was made of the blood concentration of radioactivity after the intraperitoneal and oral administration of 0.5 g/kg of succinimide. The pharmacokinetics of orally administered succinimide have been fitted to a one-compartment open model. Maximum blood concentrations were seen after about 2 h. Absorption and elimination were faster after dosage at 0.09 g/kg than after 1.0 and 2.0 g/kg. Succinimide appeared to be well absorbed, and was evenly distributed throughout the body. About 70% of an administered dose of 1.0 g/kg was eliminated within 32 h; 50% in the urine, 4% in the faeces, and 17% as14CO2 in the expired air. Approximately 90% of the radioactivity in the urine (0–24 h) was succinimide.

Key words

succinimide pharmacokinetics elimination tissue distribution 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. (1).
    Succinimide. Drugs of Today,10, 224–226 (1974).Google Scholar
  2. (2).
    Succinimide. The Merck Index, Ninth Edition, p. 1148. Merck & Co., Inc., Rahway, N.J. (1976).Google Scholar
  3. (3).
    Thomas, J., Melon, J.M., Thomas, E., Steg, A. and Aboulker, P. (1973): The role of oxalic acid in oxalic nephrolithiasis. Urinary Calculi. Proceedings of the International Symposium on Renal Stone Research, Madrid 1972. S. Karger, Basel, pp. 57–66.Google Scholar
  4. (4).
    Hodgkinson, A., Bissett, P. and Tye, J. (1975): Effect of succinimide and other drugs on oxalate excretion by rats. Urol. Internat.,30, 465–471.CrossRefGoogle Scholar
  5. (5).
    Rotolo, U., Palazzo, M.A., Finocchiaro, L., Caruselli, S. and Pavone Macaluso, M. (1976): Serum oxalate changes in patients undergoing regular maintenance hemodialysis and treated with succinimide. Kidney Internat.,9, 532.Google Scholar
  6. (6).
    Champagnac, A. and Jean, S. (1976): Influence du succinimide sur les calculs urinaires expérimentaux du rat. Compt. Rend. Soc. Biol.,170, 750–753.Google Scholar
  7. (7).
    Fuerst, E., Winderl, S., Wittwer, A. and Hoffmann, H. (1974): Verfahren zur Herstellung von Succinimid. Bundesrepublik Deutschland Offenlegungsschrift, 2, 313–386.Google Scholar
  8. (8).
    Wagner, J.G. (1975): Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Inc., Hamilton, Ill. USA.Google Scholar
  9. (9).
    Welling, P.G. (1977): Influence of food and diet on gastrointestinal drug absorption: a review. J. Pharmacokinet. Biopharm.,5, 291–334.CrossRefPubMedGoogle Scholar
  10. (10).
    Gould, R.G., Sinex, F.M., Rosenberg, I.N., Solomon, A.K. and Hastings, A.B. (1949): Excretion of radioactive carbon dioxide by rats after administration of isotopic bicarbonate, acetate, and succinate. J. Biol. Chem.,177, 295–301.PubMedGoogle Scholar
  11. (11).
    Daniel, J.W. (1969): The metabolism of L- and DL-malic acids by rats. Fd. Cosmet. Toxicol.,7, 103–106.CrossRefGoogle Scholar
  12. (12).
    Thomas, J., Thomas, E., Duburque, M.-T., Champagnac, A., Melon, J.-M. and Desgrez, P. (1974): Succinate (et succinimide), malate, oxaloacétate. Leurs effets thérapeutiques et leur mode d’action dans la lithiase oxalique. J. Urol. Nephrol.,80, 789–792.Google Scholar
  13. (13).
    Chasseaud, L.F., Down, W.H. and Kirkpatrick, D. (1977): Absorption and biotransformation of L(+)-tartaric acid in rats. Experientia,33, 998–999.CrossRefPubMedGoogle Scholar
  14. (14).
    Hautmann, R., Hering, F.J., Terhorst, B. and Lutzeyer, W. (1976): Neue Gesichtspunkte in der Behandlung des Oxalatsteinleidens. Urologe A,15, 148–152.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1978

Authors and Affiliations

  • K. E. Schulte
    • 1
  • S. Rendić
    • 1
  • G. Henke
    • 1
  • R. I. Mrongovius
    • 1
  1. 1.Institut für Pharmazeutische Chemie der Universität MünsterMünster/Westf.Federal Republic of Germany

Personalised recommendations